Expert commentary reveals unresolved safety and efficacy barriers in primate myocardial regeneration, highlighting that human embryonic stem cell therapy remains premature for clinical trials.
Recently a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a non-human primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: